Does Quartz Health Solutions Cover Dupixent?

How Quartz Health Solutions Classifies Dupixent on Its Formulary

Quartz Health Solutions, a regional insurer operating primarily in Wisconsin and parts of Illinois, Iowa, and Minnesota, places Dupixent on its specialty pharmacy tier. This classification means the drug is covered but carries higher cost-sharing than preferred generics or brand-name medications on lower tiers.

Specialty Tier Placement and What It Means

Specialty-tier drugs typically require patients to fill prescriptions through a designated specialty pharmacy rather than a standard retail location. Quartz partners with specific specialty pharmacy vendors for dispensing biologics like dupilumab. Patients on Quartz HMO, PPO, or marketplace plans will find Dupixent listed under the specialty drug benefit, which often carries coinsurance of 20-30% rather than a flat copay.

Plan Variation Across Quartz Products

Coverage details differ between Quartz's employer-sponsored plans, individual marketplace plans, and its Medicare Advantage offerings. Employer groups may negotiate custom formulary tiers that adjust cost-sharing. Marketplace plans sold through the ACA exchange must cover all FDA-approved drug categories, but the specific tier placement and prior authorization criteria can vary by metal level (Bronze, Silver, Gold, Platinum). Patients should request the most current Summary of Benefits and Coverage (SBC) document from Quartz directly, as formulary updates occur at least annually.

Prior Authorization Requirements for Dupixent

Quartz Health Solutions requires prior authorization before it will approve Dupixent claims. This step verifies medical necessity and confirms that the patient meets specific clinical criteria.

Clinical Criteria Quartz Evaluates

For atopic dermatitis, the most common Dupixent indication, Quartz generally requires documentation that the patient has moderate-to-severe disease (typically an Investigator Global Assessment score of 3 or 4, or an Eczema Area and Severity Index score of 16 or higher). The prescriber must also show that the patient tried and failed, or has a documented contraindication to, at least one conventional therapy. Topical corticosteroids, calcineurin inhibitors like tacrolimus, or systemic immunosuppressants such as methotrexate or cyclosporine count as qualifying first-line agents.

A 2020 analysis published in the Journal of Managed Care & Specialty Pharmacy found that 78% of commercial health plans required step therapy before approving dupilumab for atopic dermatitis [1]. Quartz follows this pattern.

How to Submit a Prior Authorization

The prescribing physician (usually a dermatologist, allergist, or pulmonologist) submits the prior authorization request to Quartz's pharmacy benefit manager. Required documentation includes diagnosis codes, previous treatment history with dates and outcomes, relevant lab values or clinical scores, and a letter of medical necessity if the case is complex. Quartz typically responds within 72 hours for standard requests and within 24 hours for urgent cases.

Step Therapy Protocols

Step therapy, sometimes called "fail first," requires patients to try less expensive treatments before a plan will cover a biologic. For atopic dermatitis, Quartz's step therapy protocol mirrors the American Academy of Dermatology (AAD) guidelines, which recommend topical therapies as initial management and reserve systemic agents like dupilumab for patients who do not achieve adequate control [2]. For asthma indications, documentation of uncontrolled symptoms despite medium-to-high-dose inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA) is standard.

What Dupixent Costs Under a Quartz Plan

The wholesale acquisition cost of Dupixent sits near $3,819 per month for the standard maintenance dose. Actual patient costs depend on the plan's benefit design.

Estimating Your Out-of-Pocket Expense

On a specialty tier with 25% coinsurance, a patient could face roughly $955 per month before reaching their annual out-of-pocket maximum. ACA-compliant Quartz marketplace plans cap annual out-of-pocket spending at $9,200 for individuals and $18,400 for families in 2026. Once a patient hits that ceiling, the plan covers 100% of remaining costs for the benefit year.

Patients should calculate their expected annual burden using this approach: multiply the monthly coinsurance amount by 12, then compare that figure to the plan's out-of-pocket maximum. For many patients on Dupixent, they will reach the maximum within three to five months of therapy, making the second half of the year essentially free.

Copay Assistance and the DUPIXENT MyWay Program

Sanofi operates the DUPIXENT MyWay copay assistance program for commercially insured patients. Eligible enrollees can pay as little as $0 per month for their Dupixent prescription, with the program covering up to $13,000 in annual copay or coinsurance costs [3]. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for manufacturer copay cards, though they may qualify for other assistance programs.

The program also provides injection training, nurse support, and refill reminders. Enrollment is available online or by phone at 1-844-DUPIXENT.

FDA-Approved Indications That Quartz May Cover

Dupixent holds six FDA-approved indications as of 2026. Coverage through Quartz is indication-specific, meaning the plan may approve dupilumab for one condition but deny it for another if the clinical criteria are not met.

Atopic Dermatitis

The FDA approved dupilumab for moderate-to-severe atopic dermatitis in adults in March 2017 and later expanded approval to adolescents (ages 12-17) and children as young as 6 months. In the SOLO 1 and SOLO 2 trials (combined N=1,379), 38% of adults receiving dupilumab 300 mg every two weeks achieved clear or almost-clear skin (IGA 0/1) at 16 weeks, compared with 10% on placebo [4]. This remains the most common indication for which Quartz members request Dupixent.

Asthma

For moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma, dupilumab reduced annualized severe exacerbation rates by 47.7% versus placebo in the LIBERTY ASTHMA QUEST trial (N=1,902) [5]. Quartz covers this indication for patients aged 6 years and older with blood eosinophil counts of 150 cells per microliter or higher, or with elevated fractional exhaled nitric oxide (FeNO) levels.

Chronic Rhinosinusitis with Nasal Polyps

In the SINUS-24 and SINUS-52 trials (combined N=724), dupilumab significantly improved nasal polyp scores and sinus opacification on CT imaging compared with placebo [6]. Quartz may approve Dupixent for CRSwNP after failure of intranasal corticosteroids and, in many cases, after at least one endoscopic sinus surgery.

Eosinophilic Esophagitis

The FDA approved dupilumab for eosinophilic esophagitis in May 2022 for patients aged 12 and older weighing at least 40 kg. The Part A results of the three-part LIBERTY EoE TREET study (N=81) showed that 60% of patients on dupilumab 300 mg weekly achieved histologic remission (peak esophageal intraepithelial eosinophil count of 6 or fewer per high-power field) at 24 weeks, compared with 5% on placebo [7].

Prurigo Nodularis and COPD

Dupixent received approval for prurigo nodularis in September 2022, based on the PRIME and PRIME2 trials. The FDA also approved dupilumab for chronic obstructive pulmonary disease (COPD) with type 2 inflammation in September 2024, based on the BOREAS and NOTUS trials [8]. Coverage for these newer indications may require additional documentation, as formulary committees sometimes lag behind FDA label expansions.

What to Do If Quartz Denies Your Dupixent Claim

A denial does not end the process. Patients and providers have several avenues to pursue.

Internal Appeal

Under the ACA, Quartz must provide at least one level of internal appeal. A 2022 report from the Kaiser Family Foundation found that patients who appealed denied specialty drug claims won their internal appeals approximately 40-59% of the time across commercial insurers [9]. A strong appeal letter from the treating physician, including clinical photographs, validated scoring tools (EASI, IGA), and references to the AAD guidelines or relevant clinical trial data, increases the probability of reversal.

External Review

If the internal appeal fails, patients may request an independent external review. Wisconsin's Office of the Commissioner of Insurance oversees external reviews for fully insured Quartz plans. Self-funded employer plans fall under federal ERISA rules and use federally certified independent review organizations. The external reviewer's decision is binding on the insurer.

Peer-to-Peer Review

Before a formal appeal, many denials can be resolved through a peer-to-peer phone call between the prescribing physician and the plan's medical director. This conversation allows the prescriber to present the clinical rationale directly. Physicians should prepare a concise summary: diagnosis, failed therapies with specific drugs and durations, objective severity scores, and the anticipated treatment plan with dupilumab.

Alternative Coverage Pathways and Financial Assistance

When insurance coverage is delayed or denied, patients have backup options.

Bridge Programs

The DUPIXENT MyWay program offers a limited free drug supply (typically up to two doses) while prior authorization is pending. This prevents treatment gaps during administrative processing. Patients must be enrolled in MyWay to access the bridge supply.

Patient Assistance Programs

For uninsured or underinsured patients, Sanofi's patient assistance foundation provides Dupixent at no cost to qualifying individuals. Income thresholds typically fall at or below 400% of the federal poverty level. Applications require proof of income and a prescription from the treating provider.

Specialty Pharmacy Navigation

Quartz's designated specialty pharmacy can serve as an intermediary, contacting the insurer on the patient's behalf to expedite prior authorizations and troubleshoot claim rejections. Patients should ask their specialty pharmacy case manager for help with documentation and follow-up.

Clinical Considerations Before Starting Dupixent

Safety Profile

Dupilumab's most common adverse effects include injection-site reactions (reported in approximately 10% of patients), conjunctivitis (in 8-10% of atopic dermatitis patients, per pooled trial data), and nasopharyngitis [4]. Unlike traditional immunosuppressants such as cyclosporine or methotrexate, dupilumab does not require routine blood monitoring for liver or kidney function. The AAD guidelines note that dupilumab has a "favorable safety profile relative to conventional systemic immunosuppressants" for atopic dermatitis [2].

Monitoring and Follow-Up

Quartz may require periodic reauthorization, often every 6 to 12 months, to continue covering Dupixent. The prescribing physician must document ongoing medical necessity, including updated severity scores showing treatment response. Patients who achieve and maintain clear or almost-clear skin may face questions about treatment duration, though the AAD has not recommended fixed stopping points for dupilumab in atopic dermatitis.

Drug Interactions

Dupilumab has no known clinically significant drug-drug interactions listed in its prescribing information [3]. It does not interact with cytochrome P450 enzymes. Patients may receive live or non-live vaccines while on dupilumab, though the prescribing information recommends avoiding live vaccines until more data are available.

How Dupixent Compares to Other Covered Biologics

Quartz's formulary includes several other biologic and targeted therapies for conditions that overlap with dupilumab's indications.

JAK Inhibitors for Atopic Dermatitis

Abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are oral JAK inhibitors approved for moderate-to-severe atopic dermatitis. The Heads Up trial (N=692) showed that upadacitinib 30 mg daily produced a higher rate of EASI-75 response at week 16 (71%) compared with dupilumab 300 mg every two weeks (61%), though the safety profiles differ [10]. JAK inhibitors carry boxed warnings for serious infections, malignancy, and cardiovascular events, while dupilumab does not. Quartz may prefer dupilumab as a first-line biologic given the difference in safety labeling.

Other IL-Targeting Biologics

Tralokinumab (Adbry), an IL-13-specific monoclonal antibody, is approved for atopic dermatitis in adults. The ECZTRA trials showed somewhat lower efficacy than dupilumab in indirect comparisons, though no head-to-head trial exists [11]. Formulary placement and tier preference on Quartz plans may vary based on negotiated rebates between the manufacturer and the plan's pharmacy benefit manager.

Asthma Biologics

For asthma, dupilumab competes with omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire). Each targets a different point in the type 2 inflammatory cascade. The Global Initiative for Asthma (GINA) 2024 report recommends choosing a biologic based on the patient's specific biomarker profile (eosinophils, IgE, FeNO) rather than defaulting to one agent [12]. Quartz's prior authorization criteria for asthma biologics reflect this biomarker-driven approach.

Tips for Quartz Members Seeking Dupixent Coverage

Preparation before submitting a claim reduces delays. Patients should confirm their plan's current formulary by calling the number on the back of their Quartz insurance card or checking the online formulary tool at quartzbenefits.com. Keeping a documented treatment history that includes drug names, doses, durations, and reasons for discontinuation gives the prescriber the raw material for a strong prior authorization submission.

Patients with employer-sponsored Quartz plans should ask their HR benefits coordinator whether the plan is fully insured (regulated by Wisconsin state insurance law) or self-funded (regulated by federal ERISA). This distinction affects appeal rights and external review processes.

Dupixent's average time from prior authorization submission to first injection is 7 to 14 days when documentation is complete on the first submission, based on specialty pharmacy workflow benchmarks. Incomplete submissions are the most common cause of delay.